Summary of Study ST003221

This data is available at the NIH Common Fund's National Metabolomics Data Repository (NMDR) website, the Metabolomics Workbench, https://www.metabolomicsworkbench.org, where it has been assigned Project ID PR002009. The data can be accessed directly via it's Project DOI: 10.21228/M8XJ96 This work is supported by NIH grant, U2C- DK119886. See: https://www.metabolomicsworkbench.org/about/howtocite.php

Perform statistical analysis  |  Show all samples  |  Show named metabolites  |  Download named metabolite data  
Download mwTab file (text)   |  Download mwTab file(JSON)   |  Download data files (Contains raw data)
Study IDST003221
Study TitleUntargeted NMR-lipidomic study in R7, R7sgRON, R7shDEK cells
Study SummaryRecurrent and metastatic breast cancer is frequently treatment resistant. A wealth of evidence suggests that reprogrammed lipid metabolism supports cancer recurrence. Overexpression of the RON and DEK proteins in breast cancer is associated with poor outcome. Both proteins promote cancer metastasis in laboratory models, but effects on lipid metabolite levels remain unknown. To measure RON- and DEK-dependent steady-state lipid metabolite levels, an Nuclear Magnetic Resonance (NMR)-based approach was utilized. The observed differences were then used to identify a lipid metabolism-related gene expression signature that is prognostic of overall survival (OS), distant metastasis free survival (DMFS), post-progression survival (PPS), and recurrence free survival (RFS) in patients with breast cancer. RON loss led to decreased cholesterol and sphingomyelin levels, while DEK loss increased total fatty acid levels and decreased free glycerol levels. Lipid-related genes were then queried to define a signature that predicts breast, ovarian, and lung cancer patient survival. Taken together, RON and DEK differentially regulate lipid metabolism in a manner that predicts and may promote breast cancer metastasis and recurrence.
Institute
Cincinnati Children's Hospital Medical Center
Last NameVicente-Munoz
First NameSara
Address3333 Burnet Ave
EmailSara.VicenteMunoz@cchmc.org
Phone5135172083
Submit Date2024-04-30
Raw Data AvailableYes
Raw Data File Type(s)fid
Analysis Type DetailNMR
Release Date2024-09-12
Release Version1
Sara Vicente-Munoz Sara Vicente-Munoz
https://dx.doi.org/10.21228/M8XJ96
ftp://www.metabolomicsworkbench.org/Studies/ application/zip

Select appropriate tab below to view additional metadata details:


Project:

Project ID:PR002009
Project DOI:doi: 10.21228/M8XJ96
Project Title:NMR-based lipidomics in Breast Cancer
Project Summary:Recurrent and metastatic breast cancer is frequently treatment resistant. A wealth of evidence suggests that reprogrammed lipid metabolism supports cancer recurrence. Overexpression of the RON and DEK proteins in breast cancer is associated with poor outcome. Both proteins promote cancer metastasis in laboratory models, but effects on lipid metabolite levels remain unknown. To measure RON- and DEK-dependent steady-state lipid metabolite levels, an Nuclear Magnetic Resonance (NMR)-based approach was utilized. The observed differences were then used to identify a lipid metabolism-related gene expression signature that is prognostic of overall survival (OS), distant metastasis free survival (DMFS), post-progression survival (PPS), and recurrence free survival (RFS) in patients with breast cancer. RON loss led to decreased cholesterol and sphingomyelin levels, while DEK loss increased total fatty acid levels and decreased free glycerol levels. Lipid-related genes were then queried to define a signature that predicts breast, ovarian, and lung cancer patient survival. Taken together, RON and DEK differentially regulate lipid metabolism in a manner that predicts and may promote breast cancer metastasis and recurrence.
Institute:Cincinnati Children's Hospital Medical Center
Last Name:Vicente-Munoz
First Name:Sara
Address:3333 Burnet Ave, Cincinnati, OH, 45206, USA
Email:Sara.VicenteMunoz@cchmc.org
Phone:5135172083

Subject:

Subject ID:SU003340
Subject Type:Cultured cells
Subject Species:Mus musculus
Taxonomy ID:10090
Species Group:Mammals

Factors:

Subject type: Cultured cells; Subject species: Mus musculus (Factor headings shown in green)

mb_sample_id local_sample_id Genotype
SA352072R7-7R7
SA352073R7-1R7
SA352074R7-5R7
SA352075R7-6R7
SA352076R7-2R7
SA352077R7-3R7
SA352078R7-4R7
SA352079RON-6R7sgRON
SA352080RON-7R7sgRON
SA352081RON-5R7sgRON
SA352082RON-4R7sgRON
SA352083RON-3R7sgRON
SA352084RON-1R7sgRON
SA352085RON-2R7sgRON
SA352086DEK-6R7shDEK
SA352087DEK-7R7shDEK
SA352088DEK-5R7shDEK
SA352089DEK-3R7shDEK
SA352090DEK-1R7shDEK
SA352091DEK-2R7shDEK
SA352092DEK-4R7shDEK
Showing results 1 to 21 of 21

Collection:

Collection ID:CO003333
Collection Summary:Cells were washed three times with ice-cold phosphate-buffered saline, followed by subsequent quenching with ice cold acetonitrile (CH3CN)and the addition of nano-pure water (CH3CN/H2O at 2:1.5 (V/V)) to facilitate cell scraping and collection.
Collection Protocol Filename:BC-SET1-MM.pdf
Sample Type:Breast cancer cells

Treatment:

Treatment ID:TR003349
Treatment Summary:R7 (control), R7sgRON (RON targeted), R7shDEK (DEK targeted) murine breast cancer cell lines were cultured in complete Dulbecco’s Modified Eagle Medium (DMEM) containing 5% FBS, 1% penicillin-streptomycin, and 0.2% fungizone. R7shDEK were maintained with 1 μg/mL of puromycin for selection. For NMR experiments, cells were seeded in 10 cm-plates in complete DMEM containing 5% dialyzed FBS.

Sample Preparation:

Sampleprep ID:SP003347
Sampleprep Summary:Dried organic phases (lipids) were reconstituted in 220 µL of 100% methanol-d4 containing 0.05% v/v of tetramethylsilane (TMS) (Cambridge Isotopes Lab. Andover, MA), vortexed and centrifuged at room temperature. 200 µL of the supernatant were transferred into 3 mm NMR tube.
Processing Storage Conditions:On ice
Extract Storage:On ice

Analysis:

Analysis ID:AN005282
Analysis Type:NMR
Analysis Protocol File:BC-SET1-MM.pdf
Num Factors:3
Num Metabolites:25
Units:relative abundance

NMR:

NMR ID:NM000283
Analysis ID:AN005282
Instrument Name:Bruker Avance III HD 600 MHz spectrometer
Instrument Type:FT-NMR
NMR Experiment Type:1D-1H
Spectrometer Frequency:600 MHz
NMR Probe:5 mm Broad Band Observed (BBO) Prodigy probe
NMR Solvent:MeOD
NMR Tube Size:3 mm
Shimming Method:Topshim
Pulse Sequence:noesygppr1d
Temperature:15
  logo